Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 3500
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very weak growth
Data is available to registered users only
Data is available to registered users only
About
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Data is available to registered users only
Buy
Sell